ABCL News and Press, AbCellera Biologics Inc. From 11/16/23

AbCellera (Nasdaq: ABCL) today announced that management will present at the Piper Sandler 35th Annual Healthcare Conference in New York, New York on Thursday, November 30, 2023, at 9:30 a.m. Eastern Time (6:30 a.m. Pacific Time). A live audio webcast of the presentation may be accessed thr...

2023-11-15 11:22:19 ET More on ARKG, ARKK, etc. ARKK ETF: There Are Better Options Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble ARKK: Outlook For Cathie Wood's ARK Innovation ETF Cathie Wood's ARK Invest l...

New data from AbCellera’s T-cell engager platform demonstrates that diverse CD3-binding antibodies enable optimization of T-cell engager function beyond what is possible by modifying a single CD3-binder AbCellera (Nasdaq: ABCL) today presented new data on its T-cell engager...

2023-11-03 08:22:27 ET More on pre-market losers stock Stocks To Watch: Tesla, Netflix, And AT&T Headline Big Week Of Earnings Acurx Pharma falls after mid-stage data for lead asset AstraZeneca to invest $245M in Cellectis to strengthen gene therapy portfolio ...

2023-11-03 05:30:54 ET Image source: The Motley Fool. AbCellera Biologics (NASDAQ: ABCL) Q3 2023 Earnings Call Nov 02, 2023 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics (ABCL) Q3 2023 Earnings Call Tran...

2023-11-02 21:18:10 ET AbCellera Biologics Inc. (ABCL) Q3 2023 Results Conference Call November 02, 2023 5:00 PM ET Company Participants Tryn Stimart - Chief Legal & Compliance Officer Carl Hansen - President, CEO Andrew Booth - CFO Conference Call Part...

2023-11-02 16:38:09 ET More on AbCellera Biologics AbCellera's Clinical Carousel: High Risk, Higher Stakes AbCellera Biologics Q3 2023 Earnings Preview AbCellera expands its multi-target collaboration with Regeneron Seeking Alpha’s Quant Rating on AbCe...

Total revenue of $7 million, compared to $101 million in Q3 2022 Total cumulative partnered program starts of 110, up 20% from Q3 2022 Net loss of $0.10 per share on a basic and diluted basis, compared to net earnings of $0.09 and $0.08 per share on a basic and diluted basis, resp...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

AbCellera Biologics Inc. (ABCL) is expected to report $-0.14 for Q3 2023